Cassava Sciences ( (SAVA) ) has shared an update.
On February 26, 2025, Cassava Sciences entered into a License Agreement with Yale University, granting them exclusive worldwide rights to certain intellectual property for the development and commercialization of Simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. This agreement, based on promising research by Yale, involves milestone payments up to $4.5 million and tiered royalties on net sales. The agreement reflects Cassava’s strategic focus on expanding Simufilam’s therapeutic applications, potentially impacting the treatment landscape for rare neurodevelopmental disorders.
More about Cassava Sciences
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. Their proprietary investigational drug, Simufilam, targets the filamin A protein.
YTD Price Performance: -16.36%
Average Trading Volume: 3,162,529
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $110.7M
Learn more about SAVA stock on TipRanks’ Stock Analysis page.